Zymeworks

ZYME · NASDAQ

$26.91+$1.37 (+5.36%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $25.54

Latest news

Press releaseOct 19, 6:00 AM ETGlobe Newswire
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
NewsSep 28, 1:05 PM ETVandana Singh
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
NewsSep 28, 6:12 AM ET
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Press releaseSep 28, 6:00 AM ETGlobe Newswire
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Press releaseSep 23, 4:01 PM ETGlobe Newswire
Zymeworks Completes Acquisition of Theravance Biopharma
NewsAug 26, 10:16 AM ETAvi Kapoor
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
NewsAug 25, 12:51 PM ETVandana Singh
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
Press releaseAug 25, 10:23 AM ETGlobe Newswire
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Press releaseAug 6, 4:05 PM ETGlobe Newswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Press releaseJul 16, 6:00 AM ETGlobe Newswire
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Press releaseJul 6, 11:19 AM ETPRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
NewsJun 29, 9:20 AM ETVandana Singh
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
NewsJun 29, 6:04 AM ET
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Press releaseJun 29, 6:00 AM ETGlobe Newswire
Zymeworks to Acquire Theravance Biopharma, Inc.
NewsJun 29, 5:26 AM ET
Zymeworks Said To Near $929M Deal For Theravance At $17 Per Share, Bloomberg News Reports
Press releaseJun 18, 8:00 AM ETPRNewswire
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Press releaseJun 14, 6:05 PM ETGlobe Newswire
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
NewsMar 9, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsMar 3, 1:01 PM ET
Forecasting The Future: 4 Analyst Projections For Zymeworks
NewsMar 2, 6:11 AM ET
Earnings Scheduled For March 2, 2026
Press releaseJan 11, 6:00 PM ETGlobe Newswire
Zymeworks Outlines Strategic Priorities and Outlook for 2026
NewsJan 7, 1:12 PM ETVandana Singh
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial
Press releaseNov 18, 8:45 AM ETGlobe Newswire
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
NewsNov 18, 7:34 AM ETAvi Kapoor
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Press releaseNov 18, 1:00 AM ETGlobe Newswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
NewsNov 17, 12:09 PM ETVandana Singh
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
NewsNov 17, 12:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 17, 11:39 AM ETAvi Kapoor
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
Press releaseNov 17, 10:48 AM ETGlobe Newswire
Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open
NewsNov 17, 7:23 AM ET
Market-Moving News for November 17th
NewsNov 17, 7:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsOct 24, 8:01 AM ET
5 Analysts Have This To Say About Zymeworks
Press releaseOct 15, 9:11 AM ETPRNewswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
NewsAug 22, 5:07 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsMar 10, 5:04 PM ET
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
Press releaseJan 8, 4:05 PM ETGlobe Newswire
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
NewsDec 19, 1:01 PM ET
Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)
NewsNov 22, 8:01 AM ET
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
Press releaseOct 31, 4:05 PM ETGlobe Newswire
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
NewsOct 22, 10:01 AM ET
What Analysts Are Saying About Zymeworks Stock
Press releaseSep 19, 12:08 PM ETPRNewswire
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
Press releaseAug 6, 7:00 AM ETBusiness Wire
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Zymeworks Completes Acquisition of Theravance Biopharma

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M

Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks Said To Near $929M Deal For Theravance At $17 Per Share, Bloomberg News Reports

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

Forecasting The Future: 4 Analyst Projections For Zymeworks

Earnings Scheduled For March 2, 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

12 Health Care Stocks Moving In Monday's Intraday Session

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open

Market-Moving News for November 17th

12 Health Care Stocks Moving In Monday's Pre-Market Session

Earnings Scheduled For November 6, 2025

5 Analysts Have This To Say About Zymeworks

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For May 8, 2025

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)

In-Depth Examination Of 9 Analyst Recommendations For Zymeworks

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

What Analysts Are Saying About Zymeworks Stock

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO